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Abstract
Recently, others and we identified de novo FBXO11 (F-Box only protein 11) variants as causative for a variable
neurodevelopmental disorder (NDD). We now assembled clinical and mutational information on 23 additional individuals.
The phenotypic spectrum remains highly variable, with developmental delay and/or intellectual disability as the core
feature and behavioral anomalies, hypotonia and various facial dysmorphism as frequent aspects. The mutational spectrum
includes intragenic deletions, likely gene disrupting and missense variants distributed across the protein. To further
characterize the functional consequences of FBXO11 missense variants, we analyzed their effects on protein expression and
localization by overexpression of 17 different mutant constructs in HEK293 and HeLa cells. We found that the majority of
missense variants resulted in subcellular mislocalization and/or reduced FBXO11 protein expression levels. For instance,
variants located in the nuclear localization signal and the N-terminal F-Box domain lead to altered subcellular localization
with exclusion from the nucleus or the formation of cytoplasmic aggregates and to reduced protein levels in western blot. In
contrast, variants localized in the C-terminal Zn-finger UBR domain lead to an accumulation in the cytoplasm without
alteration of protein levels. Together with the mutational data, our functional results suggest that most missense variants
likely lead to a loss of the original FBXO11 function and thereby highlight haploinsufficiency as the most likely disease
mechanism for FBXO11-associated NDDs.

Introduction
Recently, de novo variants in the F-Box protein encoding FBXO11
gene have been described as causative for a variable neurodevelopmental disorder [MIM #618 089, intellectual developmental
disorder with dysmorphic facies and behavioral anomalies
(IDDFBA); (1–3)]. Very recently, the first familial case of IDDFBA
has also been reported (4). To date, 51 individuals from 49
independent families with pathogenic or likely pathogenic
FBXO11 variants have been described (1–6). Affected individuals
show variable degrees of cognitive impairment ranging from
normal IQ with developmental delay (DD) to severe intellectual
disability (ID). Behavioral anomalies are common. Seizures and
brain abnormalities are observed in a fraction of individuals
(1–4). Growth parameters are highly variable with short stature
and microcephaly being more common than tall stature and
macrocephaly. Other frequently reported features include skeletal abnormalities, recurrent infections and vision anomalies.
Though facial dysmorphism is observed in the majority of
individuals, no recognizable facial gestalt could be delineated
(2,3). The mutational spectrum encompasses large multigene and intragenic deletions, likely gene-disrupting (LGD)
variants, single amino acid deletions and missense variants.
The latter are distributed across the protein and mostly localize
to any of the protein domains. No obvious genotype–phenotype
correlations could be established (2,3). It has therefore been
postulated that haploinsufficiency might be the most likely

disease mechanism for all described FBXO11 variants, but
gain-of function or dominant negative effects could not be
excluded (2,3).
FBXO11 belongs to the F-Box protein family, which contains
over 60 members that all carry an F-Box domain in addition
to various other protein domains (7,8). FBXO11 contains several
functional domains, including the eponymous F-Box domain,
important for interaction with S-phase kinase-associated protein 1 (SKP1) and subsequently other SCF complex components
(9). It also contains three carbohydrate binding/sugar hydrolysis
(CASH) domains, which are important for substrate recognition
(7,10) and a Zinc-finger UBR (Zf-UBR) domain, which interacts
with N-terminal degradation signals in substrate proteins and
is a characteristic feature of E3 ubiquitin ligases (11). FBXO11
constitutes a subunit of an E3-ubiquitin ligase complex, the SCF
complex (SKP1-Cullin-F-Box), which additionally includes SKP1
and Cullin 1 [CUL1 (7)]. Within the complex, FBXO11 is important
for recognition of substrates resulting in their ubiquitination
and subsequent degradation. It is also thought to play a role in
maintenance of genome stability (12). Its function has mainly
been studied in the context of different malignancies such as Bcell lymphoma (10), myelodysplastic syndrome (13), hepatocellular carcinoma (14), gastric cancer (15) and glioblastoma (16).
The functional role of FBXO11 in neurodevelopmental disorders (NDDs) and neurodevelopment in general remains elusive.
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Results
Further delineation of the clinical spectrum
All 23 individuals with FBXO11 aberrations presented with DD
and/or ID. Cognitive impairment was variable, ranging from
normal IQ with learning difficulties and attention deficits in
two individuals to severe ID in three individuals. Developmental
milestones were delayed in many cases, with age of walking
ranging from 8 months (normal) to no walking ability at
age 10 years and age of first words ranging from normal
development with bilingual upbringing to no meaningful verbal
communication at age 10 years. Behavioral anomalies were
commonly observed among individuals and included attention
deficits, anxiety and autism. Seizures were reported in nine
individuals, and two additional individuals showed abnormal
EEG but no seizures. Body measurements were also variable,
and in the normal range for the majority of cases, with short
stature observed in three individuals. Head circumference was
also in the normal range for the majority of cases, with three
individuals reported as microcephalic. Increased body weight
and/or hyperphagia were reported in four individuals. Nonspecific facial dysmorphism were reported in most individuals
(Fig. 1A). Recurrent infections and/or otitis media were reported
in 9/20 individuals. Unspecific MRI abnormalities were present
in 9/20 individuals and included white matter abnormalities,
thin corpus callosum and arachnoidal cyst. Abnormalities of
hand and feet were reported in 16/22 individuals and included
polysyndactyly, severe pronation with hindfoot malformation,
shortened metacarpals and nail hypoplasia. Skeletal anomalies
such as rhizomelic shortening of arms and legs, scoliosis,
kyphosis, enthesitis-related juvenile idiopathic arthritis and
delayed bone age were reported in 10/22 individuals. Vision
anomalies were found in 10/22 individuals and included
strabismus, myopia and hypermetropia. Hearing impairments
were reported in two cases. Other abnormalities included bowel
lymphangiectasia, hyper-IgD syndrome, chronic increase of
blood sedimentation rate without inflammatory signs and
feeding difficulties in one patient each. A summary of all
clinical information can be found in Table 1 and detailed
clinical information for each individual can be found in
Supplementary Material, Table S1.

Further delineation of the mutational spectrum
In 23 individuals, we identified four deletions, five LGD variants,
a single amino acid deletion and 13 missense variants affecting

FBXO11 (Fig. 1B). All of these variants were shown to have
occurred de novo, and for the majority paternity was confirmed
through trio exome analysis. Two deletions affected FBXO11
only partially and deleted exons 1–7 (I21) or 2–11 (I20). Both
deletions are predicted to lead to loss of the affected allele
through either loss of the start codon of all isoforms (I21), or
an out-of-frame deletion of more than a third of the protein
including the F-Box domain (I20). The other two deletions
affected exons 2–23 of FBXO11 as well as the neighboring gene
MSH6 (I22 and I23). LGD variants included three splice variants
affecting canonical splice sites. Two of these variants (c.5882A > G and c.1797 + 1G > A) are predicted to lead to out-offrame exclusion of exons 5 and 14, respectively. The third splice
variant (c.2338 + 1G > A) is predicted to lead to the exclusion of
exon 19, which is predicted to result in an in-frame deletion
of 37 amino acids affecting more than one fourth of the third
CASH domain. Lack of patient-derived material precluded
further testing of splice variants. The identified nonsense
p.(Arg742∗ ) and frameshifting p.(Ile566Phefs∗ 6) variants are
predicted to lead to nonsense-mediated mRNA decay (NMD).
All 13 missense variants affected highly conserved amino acid
residues (Supplementary Material, Fig. S1), were absent from
public databases such as gnomAD (36), and most were predicted
to be damaging by several in-silico prediction programs, but
not to affect splicing [(37); Supplementary Material, Table S2).
The missense variants are distributed across the protein and
reside in different domains. Variants localized to the putative
nuclear localization signal (NLS) as annotated by cNLS mapper
[(38); p.(Lys135Arg) and p.(Arg138Gly)], in or around the FBox domain [p.(Arg185His) and p.(Tyr206Cys)], in the CASH
domains 1 [p.(Gly421Arg), p.(Thr502Pro), p.(Gly549Arg) and
p.(Gly550Arg)], 2 [p.(Thr578Arg), p.(His650Pro) and p.(Asn679Ser)]
and 3 [p.(Met709Val)], or in the C-terminus of the protein
[p.(Asp910Val)]. The single amino acid deletion affected a highly
conserved position in the F-Box domain p.(Phe168del). All
observed variants were unique and affected distinct amino acid
positions, except for p.(Arg138Gly) and p.(Asp910Val), where a
different amino acid exchange has been reported at the same
position (2). According to the American College of Medical
Genetics and Genomics (ACMG) guidelines (39), all variants
identified here are considered likely pathogenic or pathogenic
(Supplementary Material, Tables S1 and S3).

Assessment of genotype–phenotype correlations
We considered the group of individuals described here and
summarized from previous reports large enough [n = 71, 49
independent published cases (1–6) + 22 novel cases] to
attempt characterizing genotype–phenotype correlations. For
those correlations, we excluded individual I8 who additionally has Koolen–de Vries syndrome (MIM #610 443) due to
a pathogenic variant in KANSL1, confounding the clinical
picture. Summarized clinical data of all cases can be found
in Supplementary Material, Table S3. Overweight/hyperphagia
were more common in individuals carrying LGD variants
compared to carriers of missense variants with a nominally
significant P-value [Table 1, chi-square test, 46% versus 18%
(P = 0.013)]. When comparing missense variants with only LGD
variants predicted to lead to NMD (NMD–LGD), we furthermore
found that affected individuals carrying missense variants
are significantly more often of short stature compared with
NMD-LGD carriers [27% versus 7% (P = 0.048)]. Regarding short
stature, carriers of LGDs that are predicted to escape NMD (noNMD–LGD) are phenotypically more similar to missense variant

Downloaded from https://academic.oup.com/hmg/article/31/3/440/6367979 by Washington University School of Medicine Library (M1) user on 28 April 2022

Germline variants in several other F-Box proteins have also been
linked to NDDs inherited either in autosomal recessive (17–22)
or in autosomal dominant fashion (23–26). Interestingly, defects
in genes involved in protein ubiquitination and proteasomal
degradation have recently emerged as a common theme among
NDDs [e.g. (27–35)].
We now further delineate the clinical and mutational
spectrum of a FBXO11-associated NDD by adding 23 additional
cases with de novo FBXO11 variants identified through either
chromosomal microarray testing or exome sequencing. Furthermore, we characterize the functional effects of several
published and the majority of the novel FBXO11 missense
variants. Our results show impaired expression or subcellular
localization for the majority of the missense variants, supporting
the hypothesis that FBXO11 deficiency is caused by loss of
function.

22
22/22 (100%)
15/22 (68%)
5/22 (23%)
2/22 (9%)
10/22 (45%)
14/20 (70%)
21/22 (95%)
3/20 (15%)
0/20 (0%)
4/22 (18%)
3/21 (14%)
0/21 (0%)
12/20 (60%)
10/21 (48%)
9/19 (47%)
8/19 (42%)

n
ID/DD
Mild
Moderate
Severe
Seizures/abnormal EEG
Hypotonia
Facial dysmorphism
Microcephaly
Macrocephaly
Overweight/hyperphagia
Short stature
Tall stature
Behavioral anomalies
Vision impairment
Recurrent infections
MRI abnormalities

49
49/49 (100%)
23/49 (47%)
18/49 (37%)
8/49 (16%)
10/47 (21%)
30/43 (70%)
44/46 (96%)
12/48 (25%)
3/48 (6%)
19/49 (39%)
11/48 (23%)
4/48 (8%)
36/48 (75%)
22/45 (49%)
9/23 (39%)
14/32 (44%)

All

Publishedb (%) (1–5)

71
100%
54%
32%
14%
29%
70%
96%
22%
4%
32%
20%
6%
71%
48%
43%
43%

All

Total %

n = 34
34/34 (100%)
18/34 (53%)
10/34 (29%)
6/34 (18%)
13/33 (39%)
22/31 (71%)
30/33 (91%)
4/32 (13%)
2/32 (6%)
6/34 (18%)
9/33 (27%)
2/33 (6%)
22/33 (67%)
18/31 (58%)
10/20 (50%)
15/29 (52%)

Missense/single aa deletion
n = 37
37/37 (100%)
20/37 (54%)
13/37 (35%)
4/37 (11%)
7/36 (19%)
22/32 (69%)
35/35 (100%)
11/36 (31%)
1/36 (3%)
17/37 (46%) (0.013)
5/36 (14%) (ns)
2/36 (6%)
26/35 (75%)
14/35 (40%)
8/22 (36%)
7/22 (32%)

LGD all

n = 30
30/30 (100%)
18/30 (60%)
10/30 (33%)
2/30 (7%)
6/30 (20%)
16/26 (62%)
29/29 (100%)
8/29 (28%)
1/29 (3%)
15/30 (50%) (0.008)
2/29 (7%) (0.048)
2/29 (7%)
21/28 (75%)
9/29 (31%)
6/19 (32%)
6/17 (35%)

LGD w NMD

Total (%) (P-value versus missense∗ )

n =7
7/7 (100%)
2/7 (29%)
3/7 (42%)
2/7 (29%)
1/6 (17%)
6/6 (100%)
6/6 (100%)
3/7 (43%)
0/7 (0%)
2/7 (29%) (ns)
3/7 (43%) (ns)
0/7 (0%)
5/7 (71%)
5/6 (83%)
2/3 (67%)
1/5 (20%)

LGD w/o NMD
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Notes: For individual clinical information see Supplementary Material, Tables S1 and S3, nominally significant P-values are highlighted in bold, all P-values not indicated were not significant; LGD: likely gene-disrupting variants
including frameshift mutations, nonsense mutations, splice site variants and intragenic deletions; NMD: nonsense-mediated decay; ns: not significant.
a Individual I8 from the current study was excluded from phenotypic summary due to dual diagnosis.
b For the familial cases from Lee et al. 2020 only individual 1 was included here.
∗
Significance was calculated using a chi-square test by comparison of number cases with missense variants compared to numbers with different LGD categories (all LGDs, LGD with predicted NMD and LGD without predicted NMD).

All

Variant type

Novela (%)

Table 1. Overview of phenotypes in novel and published cases and phenotypes
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of hash. LGD variants predicted to escape nonsense mediated decay are marked with a black box. Single letter amino acid codes were used due to space constraints.

carriers than to NMD–LGD carriers, and regarding overweight the
differences between LGD and missense variant carriers seem to
be driven mainly by the NMD–LGD variant carriers. Other clinical
features such as the presence of seizures, behavioral anomalies,
hypotonia, facial dysmorphism, MRI abnormalities, vision

abnormalities or recurrent infections were equally common
across groups with different mutation types. One factor that
may influence the ability to draw any genotype–phenotype
correlations is the presence of additional de novo variants of
uncertain significance in other genes that was found in six of

Downloaded from https://academic.oup.com/hmg/article/31/3/440/6367979 by Washington University School of Medicine Library (M1) user on 28 April 2022

Figure 1. Overview of the clinical and mutational spectrum in individuals with FBXO11 aberrations. (A) Clinical images of affected individuals. (B) Schematic drawing of
FBXO11 (NM_001190274.1, NP_001177203.1) with annotation of novel [top, blue (missense variants) and purple (LGD variants)] and previously published (bottom, black)
aberrations. Domains are color-coded according to InterPro (66). The spectrum encompasses large multi-gene and intragenic deletions, LGD variants, single amino acid
deletions and missense variants. Most variants are unique, recurrent variants are underlined. All variants included in the functional assays are marked with the symbol
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FBXO11 missense variants are predicted to destabilize
the protein
To further investigate possible effects of missense variants on
protein stability and function we first performed in-silico mutational modelling for six novel variants and one previously published variant [p.(Tyr506Cys); (3)] in domains where structural
information is available. The CASH domains of FBXO11 exhibit
an elongated structure that consists of right-handed β-helices
(40). All variants in this domain have an unfavorable effect on
the protein structure either by causing a loss of stabilizing interactions or by inducing steric problems [‘clashes’; (Fig. 2)]. In the
Gly421Arg and Gly549Arg variants, tiny glycines (Fig. 2A and C)
are replaced by much bulkier arginines, which results in steric
clashes (Fig. 2B and D) that potentially destabilize the protein
structure. In case of the Tyr506Cys and Asn679Ser variants the
wildtype residues form stabilizing hydrophobic (Y506; Fig. 2E)
or polar (N679; Fig. 2G) interactions with adjacent residues. In
both variants, the wildtype residue is replaced by an amino acid
with a shorter sidechain, which could result in a loss of these
stabilizing interactions (Fig. 2F and H). In the His650Pro variant,
the proline is sterically not tolerated and therefore expected to
destabilize the domain structure (not shown). Modelling of the
variants located in the F-box domain suggests that they also disturb the domain structure, either by a loss of polar interactions
(Arg185His) or by the loss of Phe168 that is central part of the
hydrophobic core (Phe168del).

SCF complex formation is not affected by FBXO11
missense variants
FBXO11 is part of the SCF ubiquitin ligase complex (7). To test
whether any of the missense variants affect formation of the
basic SCF complex, we performed co-immunoprecipitation
experiments following transient overexpression of Myc-tagged
wildtype or mutant FBXO11 for nine of the previously reported
and one novel missense variants (see Table 2). All tested
missense variants were still able to co-immunoprecipitate
CUL1, another subunit of the SCF complex, at similar levels
(Supplementary Material, Fig. S2), suggesting that SCF-complex
formation is not impaired by the tested missense variants.

FBXO11 missense variants affect subcellular
localization
FBXO11 localizes to the cytoplasm and the nucleus in HeLa
cells (Fig. 3). To investigate whether missense variants might
lead to subcellular mislocalization we tested the expression of
Myc-tagged FBXO11 constructs each carrying 1 of 17 missense
variants either described here or published previously [Table 2;
(2)] and quantified the observed phenotypes. Missense variants
p.(Lys135Arg), p.(Arg138Ser) and p.(Arg138Gly), all located in the
putative NLS sequence, abrogated subcellular localization and
led to exclusion from the nucleus in all transfected cells (Fig. 3).
Furthermore, many of the missense variants located in the FBox domain [p.(Gln156Arg) and p.(Arg185His)], CASH domains

[p.(Tyr506Cys), p.(Ile538Val), p.(Gly549Arg) and p.(Thr623Arg)]
and Zf-UBR domain [p.(Ser840Pro) and p.(Ala892Asp)] or at
the C-terminus of the protein adjacent to the Zf-UBR domain
[p.(Asp910Gly)] led to the formation of cytoplasmic aggregates
in 50–90% of transfected cells (Fig. 3 and Table 2, quantified
in Supplementary Material, Fig. S3A). Similar aggregates were
present in only 10% of wildtype cells. To rule out that the
observed aggregates are purely an overexpression artifact,
we confirmed the presence of the aggregation phenotype
for some of the variants also when transfecting lower doses
of FBXO11 containing plasmid (200 ng per 12 well versus
400 ng per 12 well; Supplementary Material, Fig. S3B and C).
We furthermore also confirmed the formation of cytoplasmic aggregates albeit at a lower frequency of 30–50% of
cells for some variants in another cell type, HEK293 cells
(Supplementary Material, Fig. S4). To investigate the nature of
these aggregates, we picked several of the aggregate forming
variants from the different domains [F-Box: p.(Gln156Arg), CASH
1: p.(Gly549Arg) and CASH 2: p.(Thr623Arg)] and performed
co-staining with markers for different subcellular organelles,
namely the endoplasmic reticulum (ER), the Golgi apparatus,
and early or late endosomes/lysosomes. The aggregates did not
co-localize with any of the markers, suggesting that they are not
associated with any organelle (Supplementary Material, Fig. S5).
We next tested whether these aggregates contain other
components of the SCF complex by co-staining with antibodies
against CUL1 and SKP1. Although most variants tested did
not show evidence of co-localization with the SCF complex
(Supplementary Material, Fig. S6), we found that aggregates of
variant p.(Ser840Pro) partially co-localize with CUL1 in the
cytosol, suggesting that some, but not all of those aggregates
may be SCF complexes (Supplementary Material, Fig. S6). We
finally performed co-staining with an FK2-antibody, which
stains ubiquitinated proteins. However, we were also not able
to find any evidence of co-localization of aggregates with
the FK2 signal (Supplementary Material, Fig. S7), leaving the
nature of the observed aggregates unclear for the majority
of variants.

Protein expression is reduced for many FBXO11
missense variants
We also investigated whether FBXO11 missense variants
affect protein expression. We therefore performed western
blotting analysis after overexpression of Myc-tagged wildtype
or mutant FBXO11. To control for transfection differences we
co-transfected a FLAG-tagged control protein (MEF2C), which
was used for quantification of blots. We found that missense
variants located in the NLS and the F-Box domain all resulted
in reduced expression levels of FBXO11 (Fig. 4). For missense
variants located in one of the three CASH domains, expression
was more variable and reduced in four mutant constructs
[p.(Gly421Arg), p.(Tyr506Cys), p.(Gly549Arg) and p.(Asn679Ser)],
whereas it remained unchanged for two others [p.(Ile538Val)
and p.(Thr623Arg)]. Variants affecting the Zf-UBR domain or
the C-terminus of the protein did not seem to alter FBXO11
expression.

Integration of functional assay data
FBXO11 missense variants can lead to a spectrum of functional
effects (Fig. 4C), ranging from abnormal localization combined
with reduced protein expression for eight variants, abnormal
localization with normal protein levels for five variants or
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the previously published cases (2,3). It must be noted that none
of the observed differences remain statistically significant when
correcting for multiple testing. Thus, even larger clinical cohorts
will be needed to define potential differences. In summary, while
we can observe subtle phenotypic differences between carriers
of either missense or LGD variants, no distinct phenotypic
groups could be established.
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H594 and Y598. (E) Y506 forms hydrophobic interactions (green arrows) with H508 and W529. (F) These interactions cannot be formed by the shorter cysteine sidechain
in the Y506C variant. (G) N679 forms a sidechain hydrogen bond (green line) to N656. (H) This interaction cannot be formed by the shorter serine sidechain in the N679S
variant.

reduced protein expression with normal localization for three
variants. Only one variant did not show any functional defects
in the assays tested here [p.(Pro905Arg)]. N-terminal variants
localized in the NLS or the F-Box domain all affect localization

and stability of FBXO11. C-terminal variants located in the
Zf-UBR domain or the very C-terminus are likely to affect
localization, but not protein expression levels. For the variants
in the CASH domains, no specific pattern could be observed
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Figure 2. FBXO11 variants affect stability of the protein. Results of mutational modelling for three novel [p.(Gly421 Arg), p.(Gly549His) and p.(Asn679Ser)] and one
previously published missense variants [p.(Tyr506Cys; (3) ]are shown. (A) Vicinity of G421 (dark grey) within the β-helix (β-strands are indicated as yellow arrows and
key residues are shown in space-filled presentation). (B) The R421 sidechain (dark grey) points towards the interior of the β-helix and forms steric clashes (red arrows)
with the sidechains of I400, I415 and H418. (C) Vicinity of G549 within the β-helix. (D) The bulkier R549 sidechain forms steric clashes (red arrows) with the sidechains of
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Table 2. Overview of functional testing results of FBXO11 missense variants

Domainb

Modelling

Complex
formation

Localization
N+C

Expression level
100

Variant
reported

K135R (K51R)
R138G (R54G)
R138S (R54S)
Q156R (Q72R)
F168del (F84del)
R185H (R101H)
Y206C (Y122C)
G421R (G337R)
T502P (T418P)
Y506C (Y422C)
I538V (I454V)
G549R (G465R)
G550R (G466R)
T578R (T494R)
T623R (T539R)
H650P (H566P)
N679S (N595S)
M709V (M625V)
S840P (S756P)

NLS
NLS
NLS
F-Box
F-Box
F-Box

Np
Np
Np
Np
Loss of stabilizing interaction
Loss of stabilizing interaction
Np
Steric clashes
Nd
Loss of stabilizing interaction
Loss of stabilizing interactionc
Steric clashes
Nd
Nd
Electrostatic repulsionc
Destabilization of domain structure
Loss of stabilizing interaction
Np
Steric clashesc

Nd
Normal
Normal
Normal
Nd
Nd
Nd
Nd
Nd
Normal
Normal
Nd
Nd
Nd
Normal
Nd
Nd
Nd
Normal

47 ± 14
60 ± 10
53 ± 14
49 ± 13
69 ± 7
55 ± 14
43 ± 8
55 ± 9
Nd
59 ± 12
98 ± 6
47 ± 10
Nd
Nd
106 ± 12
Nd
57 ± 6
Nd
116 ± 27

0.03
0.02
0.03
0.03
0.02
0.04
0.004
0.009
Nd
0.03
0.8
0.01
Nd
Nd
0.7
Nd
0.005
Nd
0.6

This study
This study
(2)
(2)
This study
This study
This study
This study
This study
(3)
(2)
This study
This study
This study
(2)
This study
This study
This study
(2)

A892D (A808D)
P905R (P821R)
D910G (D826G)
D910V (D826V)

Zf-UBR

Conformational changec
Np
Np
Np

Normal
Normal
Normal
Nd

C
C
C
Granula
Granula
Granula
N+C
N+C
Nd
Granula
Granula
Granula
Nd
Nd
Granula
Nd
N+C
Nd
Granula,
coloc.
With SCF
Granula
N+C
Granula
Nd

120 ± 21
95 ± 30
118 ± 21
Nd

0.4
0.9
0.4
Nd

(2)
(2)
(2)
This study

CASH 1
CASH 1
CASH 1
CASH 1
CASH 1
CASH 1
CASH 2
CASH 2
CASH2
CASH 2
CASH 3
Zf-UBR

Nd: not determined, Np: not possible, N: nuclear, C: cytoplasmic.
a Annotation according to the longest isoform NP_001177203.1 (and shorter cloned isoform NP_079409.3).
b Domain structure according to Interpro.
c Reported in Gregor et al. (2).

with all variants affecting either localization, expression levels
or both.

Discussion
With 23 novel cases reported in this study, a total of 74 individuals from 72 independent families with pathogenic or likely
pathogenic FBXO11 aberrations according to the ACMG guidelines have been described to date (1–5). The clinical spectrum
among all cases remains highly variable with DD and/or ID
of varying severity as the only feature present in all individuals. Clinical variability is also reflected by the fact that the
first familial cases with a LGD variant in FBXO11 and a mild
phenotype have been described recently (4). Most pathogenic
variants in FBXO11, however, have occurred de novo. The most
frequent additional clinical features include behavioral anomalies, hypotonia, vision impairment and variable non-specific
facial dysmorphism alongside with various other anomalies.
Recurrent infections and/or otitis media have been reported in
several cases, which is notable as also a heterozygous Fbxo11
mouse model showed increased susceptibility to chronic otitis
media (41), which may point to a role of FBXO11 in immune
response. Cleft lip/palate has been reported in five individuals, but does not seem to be a common feature in FBXO11associated NDDs, though reported in two homozygous Fbxo11
mouse models (41). Of note, the deletions in individuals I22 and
I23 as well as three published cases (2,3,6) also included the
neighboring MSH6 gene, loss-of-function variants in which are
responsible for Lynch syndrome (MIM #120 435). These individuals may therefore have an increased risk of colon cancer and

other types of tumors (42,43). Very recently, a potential role for
FBXO11 in a diffuse large B-cell lymphoma was discussed in an
individual with DD and a deletion of FBXO11 and MSH6 (6). Larger
cohorts and longitudinal monitoring are necessary to elucidate
whether in addition to somatic FBXO11 variants also germline
variants may predispose to various malignancies. It is noteworthy that for several NDD genes, in which somatic variants
have been associated with various malignancies, no increased
tumor risk has been observed in NDD cases so far, for example
ARID1B, germline variants in which cause Coffin-Siris syndrome
[MIM#135 900; (44)].
In addition to the clinical variability, FBXO11-associated
NDDs also show variability in the mutational spectrum, which
ranges from different types of intragenic deletions and LGD
variants to missense variants and single amino acid deletions.
No mutational hotspots or preferred mutation types seem to
be present, which is in line with the intolerance of FBXO11
to loss-of-function variants [pLI = 1; (45)] and the findings that
missense variants in haploinsufficient genes tend to not cluster
in specific protein regions (46). Also the C-terminal clustering
of missense and likely-gene disrupting variants observed in
our initial report (2) is not confirmed in this larger cohort. It is
notable, however, that seven of the LGD variants are located at
the very C-terminus of FBXO11 in the last exon and are therefore
predicted to escape nonsense-mediated decay (47). This may
result in a shorter stable protein that lacks part of the Zf-UBR
domain or in a shorter protein with abnormal folding, abnormal
stability or reduced half-life. Lack of patient-derived material,
however, precluded functional testing. Through investigating
genotype–phenotype correlations, we found that obesity may be
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wildtype or mutant Myc-FBXO11. Cells were fixed 48 h post transfection and stained with an anti-Myc antibody. Images were taken on a Axioimager Z2 with Apotome.
Scale bar 20 μM. Arrows point to subcellular aggregates present in several mutants.

more common in individuals carrying LGD variants compared
with missense variant carriers. In addition, short stature may
be more common in individuals carrying missense variants
compared with carriers of LGD variants that are predicted to
lead to NMD. Those potential differences, however, are subtle
and insufficient to establish distinct phenotypic groups related
to particular variants. Therefore, the lack of clear phenotype
separation based on different variant types suggests that
functional consequences of LGDs and missense variants may

be similar and that loss-of function and haploinsufficiency may
be the common pathomechanism.
To experimentally validate this hypothesis, we performed
several functional assays on 17 different missense variants
located in various functional domains. We thereby aimed to
assess functional effects and to establish whether differences in
these may contribute to the extremely large clinical variability.
Of note, these assays can only be considered as additional
evidence, but are neither necessary nor sufficient to prove
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Figure 3. FBXO11 variants affect subcellular localization. Schematic drawing of FBXO11 on top left indicates variants with altered subcellular localization in different
colors (nuclear exclusion: purple, cytoplasmic aggregates: blue). For immunofluorescence analysis HeLa cells were transiently transfected with 400 ng per 12 well of
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drawing of protein with mutations color-coded according to results of functional assays (red: mislocalization and reduced expression, green: mislocalization, blue:
reduced protein expression, black: no functional defect observed).

pathogenicity of specific variants alone. Based on our data,
tested missense variants do not seem to impair interaction with
the SCF complex, which is thought to be mediated by the F-Box
of FBXO11 (9). Currently knowledge about amino acids critical for
this interaction is lacking. However, we found that the majority

of FBXO11 variants resulted in abnormal localization of the protein, either through exclusion from the nucleus or by accumulation in cytoplasmic aggregates. As the FBXO11-containing SCF
E3-ubiquitin ligase complex functions primarily in the nucleus
(10), the exclusion of FBXO11 from the nucleus is likely to lead
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Figure 4. FBXO11 variants affect protein expression levels. (A) Representative image of western blots used for quantification of FBXO11 expression levels is shown.
(B) Quantification of FBXO11 protein levels from western blotting. Value of wildtype FBXO11 was set to 100. Experiments were repeated at least 4 times. Individual
values are shown as dots with mean values shown as bars with SEM. P-values were calculated using a one sample t-test with the hypothetical mean set to 100 and a
significance threshold of < 0.05 (∗ < 0.05, ∗∗ < 0.01). (C) Schematic overview of different functional consequences observed for tested missense variants with schematic
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function, and based on the variant location, de novo occurrence
and absence in population databases we still consider this variant likely pathogenic. It furthermore highlights the challenges
in characterizing various functionally diverse missense variants
in one gene, both molecularly and functionally. Such diversity
of functional effects of missense variants has already been
shown for other NDDs, for example for TCF4 variants causing
Pitt-Hopkins syndrome (MIM #610 954) or variants in UBE3A
causing Angelman syndrome (MIM #105 830). For UBE3A, which
encodes another nuclear E3 ubiquitin ligase, missense variants
have been shown to affect subcellular localization, protein
stability and catalytic activity (53). For TCF4, which encodes a
transcription factor, missense variants can affect DNA binding,
dimerization, transactivation capabilities as well as protein
stability and subcellular localization (50). For both disorders,
the general disease pathomechanism is haploinsufficiency, and
the diverse functional effects are all predicted to abrogate the
protein’s original function.
Our data suggest that location of missense variants in the
FBXO11 protein influences their functional effects. Variants in
the NLS and the F-Box affect localization and expression, variants in the Zf-UBR domain and the C-terminal region tend to
affect localization only, whereas the effect of variants in the
CASH domains is more variable. Therefore, variant location does
not seem to be the sole determining factor, and prediction
of functional defects based on variant location alone is likely
not possible. In general, the functional diversity is expected to
lead to similar downstream loss-of-function effects. For variants with altered localization only, specific gain-of function
effects are not likely, but cannot be excluded. In line with this,
levels of ID tend to be more severe in individuals with missense variants affecting subcellular localization only (0 out of
5 with mild DD/ID versus 4 out of 9 for other missense variants tested), but more cases would be necessary to see if this
trend holds true. Clinical variability may therefore partially be
explained not only by mutation type but also by its specific
functional effects although to date numbers are still too small
in different mutation subgroups to draw more detailed conclusions.
In summary, we expand the clinical and mutational spectrum
of FBXO11-associated NDD and provide evidence that while
some clinical variability may be influenced by mutation type and
location, most missense variants and LGD variants are likely to
function through a shared pathomechanism of loss-of function
and haploinsufficiency.

Materials and Methods
Patients and patient material
Personal communication with colleagues following the initial
report (2) and using GeneMatcher (54) and Decipher (55) allowed
us to assemble the clinical and mutational data of 23 individuals
with FBXO11 variants. Testing in collaborating centers was performed either in the setting of routine diagnostics without the
requirement for institutional ethics approval or within research
settings approved by the ethical review board of the respective
institutions (for details see Supplementary Material, Table S1).
Variants were identified through either chromosomal microarray testing (I21 and I23), trio exome sequencing (I2–6, I9, I11–
13, I16 and I18–20, I22), single exome (I8, I10 and I14), gene
panel analysis (I1 and I17) or exome pool seq (I7). Paternity was
confirmed for 15 cases through trio exome sequencing (also see
Supplementary Material, Table S1). Informed consent for testing
and for publication of mutational and clinical data was obtained
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to a loss of an important nuclear function. Consistently, known
target proteins of FBXO11 also include various transcriptional
regulators known to be localized to the nucleus such as BCL-6
and BAHD1, for example (10,48). Furthermore, for another F-box
protein, FBXW7, subcellular mislocalization and exclusion from
nucleus has been suggested as the key functional impairment
for different somatic variants implicated in various cancers
(49). On the other hand, abnormal cytoplasmic aggregation
of FBXO11 observed for 10 missense variants from the F-Box,
CASH 1 and 2 and Zf-UBR domains is also likely to interfere
with its original nuclear function. The aggregates could possibly
represent overexpression artifacts from abnormal proteins that
overwhelm the cellular degradation machinery. It is, however,
notable that these aggregates were also present when transfecting lower amounts of plasmid, in another cell type, and were
hardly found in cells overexpressing wildtype FBXO11, therefore
suggesting that aggregation is related to the specific variants. As
the exact function of FBXO11 in neurons is not well understood,
the consequences of the observed aggregates are not clear, but
an effect through partial mislocalization of FBXO11 in these
cytoplasmic aggregates seems plausible. We therefore consider
that these missense variants may render FBXO11 more prone to
aggregation likely leaving the protein non-functional, which has
also been observed in other NDDs (50). For one FBXO11 mutant
construct, carrying a variant affecting the Zf-UBR domain, aggregates possibly partially co-localized with components of the SCF
complex in the cytoplasm. Whether these complex aggregates
represent SCF complexes and whether these complexes may
be functional remains elusive and rather unlikely, especially in
light of the nuclear role of the SCF complex (10).
In addition, about half of the variants tested showed reduced
expression levels, partially overlapping with variants showing
abnormal localization. This was true for all variants affecting the
NLS and the F-Box domain. Several, but not all of the missense
variants in the CASH 1 and 2 domains also led to reduced
FBXO11 expression levels. In-silico mutational modelling data
predicted destabilizing effects for variants in the CASH domains
due to either steric clashes or loss of stabilizing interactions. Our
functional data suggest that this destabilization can be reflected
by either reduced expression and/or aggregation likely due to
misfolding of the CASH domain. Interestingly, somatic FBXO11
missense variants found in various cancer cell lines are mostly
affecting CASH domains, are also predicted to lead to a loss of
FBXO11 function (10), but are unique from germline variants
seen in NDDs. Together with our expression data it therefore
seems plausible that these variants with reduced FBXO11 levels
result from an unstable protein, which is subsequently degraded.
This would suggest that these variants act as hypomorphs and
likely lead to a partial loss of FBXO11. However, we cannot rule
out the possibility that synthesis of the affected mutant protein
is impaired. In general, for missense variants in haploinsufficient genes it has been shown that they are more likely to function through destabilizing protein structure leading to a loss-of
function than to gain-of function or dominant negative effects
(51). Furthermore, pathogenic missense variants are enriched
for variants affecting protein stability compared with benign
variants (52).
Overall, we found that most FBXO11 missense variants
affect either subcellular localization, protein expression levels
or both. Only one missense variant [p.(P905R)] did not show
functional effects in our localization and expression assays.
Effects of this and other variants on distinct functions such
as for example ubiquitination of FBXO11 target proteins were
not tested here, but would be interesting to explore in future
studies. This does not rule out an effect of this variant on FBXO11
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Zeiss Axio Imager Z2 Apotome microscope with a 63x objective
and analyzed in ImageJ [v1.52; (65)].

Protein expression analysis
Missense variants were tested for their potential predicted
effects in splicing using SpliceAI (37). Alignments for conservation analysis of missense variants were performed using
Clustalw2 (56,57). Identification of FBXO11 NLS was achieved
using the online tool cNLS mapper (38). Structural modelling
of the CASH domains was performed with HHpred (58) and
Modeller (59) based on the crystal structures of the alginate
epimerase AlgG [PDB:4OZZ, 4NK6; (60)]. The F-Box domain was
modelled with Swiss-Model (61) based on the crystal structure
of FBXL5 [PDB: 6VCD; (62)]. Mutations were modelled with
Swiss-Model (61), and the Phe168 deletion was modelled with
ModLoop (63). RasMol (64) was used for structure analysis and
visualization.

Plasmids construction
An expression plasmid containing human FBXO11 (NM_025133.4)
and the respective negative control plasmid were obtained from
Sino Biologicals, Beijing, China (FBXO11-Myc: HG13948-CM and
pCMV-Myc: CV014). Variants from affected individuals are annotated according to the longest FBXO11 isoform (NM_001190274.1).
Corresponding variants of both isoforms are indicated in
Table 2.
Seventeen missense variants observed in affected individuals in this study or previously published (2) were introduced into
the plasmid using a modified version of the Quik-Change sitedirected mutagenesis kit (Stratagene, Agilent, Sanat Clara, CA,
USA; Table 2). In addition, an expression plasmid containing the
MEF2C open reading frame was used as a transfection and normalization control (MEF2C-FLAG: HG12320-CF, Sino Biologicals,
Beijing, China).

Immunofluorescence
HeLa cells were grown on coverslips, transiently transfected
using jetPrime (Polyplus transfection, Illkirch, France) with either
wildtype FBXO11 or one of the mutant constructs and fixated
with 4% paraformaldehyde in PBS for 10 min. Immunofluorescence stainings were performed three times. HeLa cells were
transfected with 400 ng plasmid per 12 well. To confirm specificity of aggregates a test experiment was performed with 200 ng
per 12 well in Hela cells as well as in HEK293 cells (500 ng per 12
well). Staining was performed with antibodies against FBXO11
(NB100-59826, Novus Biologicals, Centennial, CO, USA 1:200), Myc
(M4439, Sigma-Aldrich, St. Louis, MO, USA 1:500), EEA1 (610 456,
BD Biosciences, Franklin Lakes, NJ, USA 1:200), GOLGIN-97 (A21270, Thermo Scientific, Waltham, MA, USA 1:100), LAMP-1
(sc-20 011, Santa Cruz Biotechnology, CA, USA 1:500), SEC31A
(612 350, BD Biosciences, Franklin Lakes, NJ, USA 1:1000), SKP1
(2156, Cell Signaling, Cambridge, UK; Millipore, Burlington, MA,
USA 1:50), CUL1 (sc-17 775, Santa Cruz Biotechnology, CA, USA
1:50), FK2 (04–263, Millipore, Burlington, MA, USA 1:500) at indicated dilutions. Secondary antibodies used were Alexa Fluor 488
goat anti-mouse (A11001), Alexa Fluor 546 donkey anti-rabbit
antibodies (A10040), Alexa Fluor 488 goat anti-rabbit (A11008)
and Alexa Fluor 546 donkey anti-mouse (A10036, all Thermo
Scientific, Waltham, MA, USA). Nuclei were counterstained with
DAPI (Serva, Heidelberg, Germany). Images were taken with a

HEK293 cells were transiently transfected with wildtype or
mutant FBXO11 and a plasmid containing MEF2C-FLAG as a
control for transfection efficiency (1.2 μg of FBXO11 plasmid
and 500 ng of MEF2C plasmid per 6 well). Forty-eight hours post
transfection cells were harvested in lysis buffer (100 mm TRIS–
HCl pH 8, 150 mm NaCl, 1 mm EDTA and 1% Triton X-100). For
western blotting, proteins were separated on stain-free 4–20%
Mini-PROTEAN TGX Precast Protein Gels (Bio-Rad), and blots
were stained with anti-Myc (1:5000), anti-FBXO11 (1:2500), antiFLAG (7425, Sigma-Aldrich, St. Louis, MO, USA 1:5000) and antiGAPDH (2118, Cell Signaling Technology, Cambridge, UK 1:5000)
antibodies. Blots were stained with SuperSignal West Femto
Maximum Sensitivity Substrate, scanned using the ChemiDoc
Imaging System (Bio-Rad, 17 001 401) and analyzed using the
Image Lab software version 6.0.0 (Bio-Rad). Band intensity of the
target protein FBXO11-Myc was normalized to the expression
of the transfection control MEF2C-FLAG. Significance was
calculated using a one sample t-test with theoretical value set
to 100.

Co-immunoprecipitation
HEK293 cells were transiently transfected with wildtype or
mutant FBXO11 plasmids (1.5 μg per 6 well). Cells were scraped
from the culture dish in lysis buffer (100 mm TRIS–HCl pH 8,
150 mm NaCl, 1 mm EDTA, 1% Triton X-100). Immunoprecipitation was performed with Protein A Mag Sepharose bead
suspension (GE Healthcare, Boston, MA, USA), incubated with the
sample and anti-Myc antibody (M4439, Sigma-Aldrich, St. Louis,
MO, USA) at 4◦ C overnight. Subsequently, beads were washed in
lysis buffer, and samples were eluted with 1x Lämmli buffer.
SDS-page and western blotting was performed as described
previously.

Supplementary Material
Supplementary Material is available at HMG online.
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